WASHINGTON (dpa-AFX) - Impax Laboratories, Inc. (IPXL) announced that it has acquired two generic products from Actavis plc (ACT) for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.
The company said the acquisition includes one product marketed under an Abbreviated New Drug Application or ANDA - Ursodiol tablet - and one approved ANDA that is not yet marketed - Lamotrigine orally disintegrating tablet or ODT.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer